Exchange Bulletin
Stem Cell Therapeutics Corp. (SSS) To Trade On Toronto Stock Exchange
Stem Cell Therapeutics Corp. (the "Company") - An application has been granted for the original listing in the Industrial category of 346,377,674 common shares (the "Shares") of which 124,377,031 Shares will be issued and outstanding and 222,000,643 Shares will be reserved for issuance.
The Shares will be listed and posted for trading at the opening on Tuesday, April 22, 2014.
The Company is subject to the reporting requirements of Section 501 of the TSX Company Manual.
Stock Symbol: "SSS" | CUSIP: 858572 40 7 | Trading Currency: CDN$ |
Temporary Market Maker: | RBC Capital Markets |
Other Markets: | The Shares were listed on TSX Venture Exchange (Symbol: SSS) on January 11, 2005. The Shares will be delisted from TSX Venture Exchange on April 22, 2014, upon commencement of trading on TSX. |
Head Office Address: | 96 Skyway Avenue Toronto, Ontario M9W 4Y9 |
Head Office Telephone Number: | (416) 595-0627 x232 |
Fax Number: | (416) 595-5835 |
Email Address: | jparsons@stemcellthera.com |
Website: | www.stemcellthera.com |
Investor Relations Contact: | James Parsons Chief Financial Officer (416) 595-0627 x232 jparsons@stemcellthera.com |
Incorporation: | The Company was incorporated under the Business Corporations Act (Alberta) on March 31, 2004 as Neurogenesis Biotech Corp. On October 19, 2004, the Company amended its articles of incorporation to change its name from Neurogenesis Biotech Corp. to Stem Cell Therapeutics Corp. On November 7, 2013 the Company was continued under the Business Corporations Act (Ontario). |
Fiscal Year End: | December 31 |
Nature of Business: | The Company is an immune-oncology company advancing cancer stem cell discoveries into novel and innovative cancer therapies. Building on over half a century of leading and ground-breaking Canadian immunology and stem cell research, the Company is supported by established links to multiple Toronto academic research institutes and cancer treatment centres that represent one of the world's most acclaimed oncology research hubs. |
Chief Financial Officer: | James Parsons |
Corporate Secretary: | James Parsons |
Transfer Agent & Registrar: | Computershare Investor Services Inc. at its principal office in Toronto. |
Dividends: | The Company has not declared or paid any cash dividends on its Shares to date. The payment of dividends in the future will be dependent on earnings and financial conditions and on such other factors as the board of directors considers appropriate. There is no present intention by the board of directors to pay dividends on the Shares. |